Drug – bio-affecting and body treating compositions – Whole live micro-organism – cell – or virus containing – Genetically modified micro-organism – cell – or virus
Reexamination Certificate
2001-10-01
2003-08-26
Crouch, Deborah (Department: 1632)
Drug, bio-affecting and body treating compositions
Whole live micro-organism, cell, or virus containing
Genetically modified micro-organism, cell, or virus
C424S093600, C514S04400A, C435S320100
Reexamination Certificate
active
06610290
ABSTRACT:
TECHNICAL FIELD
The present invention relates generally to DNA delivery methods. More particularly, the invention relates to the use of recombinant adeno-associated virus (AAV) virions for delivery of a selected gene to muscle cells and tissue. The method provides for sustained, high-level expression of the delivered gene.
BACKGROUND OF THE INVENTION
Gene delivery is a promising method for the treatment of acquired and inherited diseases. Muscle tissue is an appealing gene delivery target because it is readily accessible, well-differentiated and nondividing. Barr and Leiden (1991)
Science
254:1507-1509. These properties are important in the selection of appropriate delivery strategies to achieve maximal gene transfer.
Several experimenters have demonstrated the ability to deliver genes to muscle cells with the subsequent systemic circulation of proteins encoded by the delivered genes. See, e.g., Wolff et al. (1990)
Science
247:1465-1468; Acsadi et al. (1991)
Nature
352:815-818; Barr and Leiden (1991)
Science
254:1507-1509; Dhawan et al. (1991)
Science
254:1509-1512; Wolff et al. (1992)
Human Mol. Genet.
1:363-369; Eyal et al. (1993)
Proc. Nat. Acad. Sci. USA
90:4523-4527; Davis et al. (1993)
Hum. Gene Therapy
4:151-159.
Genes have been delivered to muscle by direct injection of plasmid DNA, such as described by Wolff et al. (1990)
Science
247:1465-1468; Acsadi et al. (1991)
Nature
352:815-818; Barr and Leiden (1991)
Science
254:1507-1509. However, this mode of administration generally results in sustained but low levels of expression. Low but sustained expression levels may be effective in certain situations, such as for providing immunity.
Viral based systems have also been used for gene delivery to muscle. For example, human adenoviruses are double-stranded DNA viruses which enter cells by receptor-mediated endocytosis. These viruses have been considered well suited for gene transfer because they are easy to grow and manipulate and they exhibit a broad host range in vivo and in vitro. Adenoviruses are able to infect quiescent as well as replicating target cells and persist extrachromosomally, rather than integrating into the host genome.
Despite these advantages, adenovirus vectors suffer from several drawbacks which make them ineffective for long term gene therapy. In particular, adenovirus vectors express viral proteins that may elicit an immune response which may decrease the life of the transduced cell. This immune reaction may preclude subsequent treatments because of humoral and/or T cell responses. Furthermore, the adult muscle cell may lack the receptor which recognizes adenovirus vectors, precluding efficient transduction of this cell type using such vectors. Thus, attempts to use adenoviral vectors for the delivery of genes to muscle cells has resulted in poor and/or transitory expression. See, e.g., Quantin et al. (1992)
Proc. Natl. Acad. Sci. USA
89:2581-2584; Acsadi et al. (1994)
Hum. Mol. Genetics
3:579-584; Acsadi et al. (1994)
Gene Therapy
1:338-340; Dai et al. (1995)
Proc. Natl. Acad. Sci. USA
92:1401-1405; Descamps et al. (1995)
Gene Therapy
2:411-417; Gilgenkrantz et al. (1995)
Hum. Gene Therapy
6:1265-1274.
Gene therapy methods based upon surgical transplantation of myoblasts has also been attempted. See, e.g., International Publication no. WO 95/13376; Dhawan et al. (1991)
Science
254:1509-1512; Wolff et al. (1992)
Human Mol. Genet.
1:363-369; Dai et al. (1992)
Proc. Natl. Acad. Sci. USA
89:10892-10895; Hamamori et al. (1994)
Hum. Gene Therapy
5:1349-1356; Hamamori et al. (1995)
J. Clin. Invest.
95:1808-1813; Blau and Springer (1995)
New Eng. J. Med.
333:1204-1207; Leiden, J. M. (1995)
New Eng. J. Med.
333:871-872; Mendell et al. (1995)
New Eng. J. Med.
333:832-838; and Blau and Springer (1995)
New Eng. J. Med.
333:1554-1556. However, such methods require substantial tissue culture manipulation and surgical expertise, and, at best, show inconclusive efficacy in clinical trials. Thus, a simple and effective method of gene delivery to muscle, resulting in long-term expression of the delivered gene, would be desirable.
Recombinant vectors derived from an adeno-associated virus (AAV) have been used for gene delivery. AAV is a helper-dependent DNA parvovirus which belongs to the genus Dependovirus. AAV requires infection with an unrelated helper virus, such as adenovirus, a herpesvirus or vaccinia, in order for a productive infection to occur. The helper virus supplies accessory functions that are necessary for most steps in AAV replication. In the absence of such infection, AAV establishes a latent state by insertion of its genome into a host cell chromosome. Subsequent infection by a helper virus rescues the integrated copy which can then replicate to produce infectious viral progeny. AAV has a wide host range and is able to replicate in cells from any species so long as there is also a successful infection of such cells with a suitable helper virus. Thus, for example, human AAV will replicate in canine cells coinfected with a canine adenovirus. AAV has not been associated with any human or animal disease and does not appear to alter the biological properties of the host cell upon integration. For a review of AAV, see, e.g., Berns and Bohenzky (1987)
Advances in Virus Research
(Academic Press, Inc.) 32:243-307.
The AAV genome is composed of a linear, single-stranded DNA molecule which contains approximately 4681 bases (Berns and Bohenzky, supra). The genome includes inverted terminal repeats (ITRs) at each end which function in cis as origins of DNA replication and as packaging signals for the virus. The internal nonrepeated portion of the genome includes two large open reading frames, known as the AAV rep and cap regions, respectively. These regions code for the viral proteins involved in replication and packaging of the virion. For a detailed description of the AAV genome, see, e.g., Muzyczka, N. (1992)
Current Topics in Microbiol. and Immunol.
158:97-129.
The construction of recombinant AAV (rAAV) virions has been described. See, e.g., U.S. Pat. Nos. 5,173,414 and 5,139,941; International Publication Numbers WO 92/01070 (published Jan. 23, 1992) and WO 93/03769 (published Mar. 4, 1993); Lebkowski et al. (1988)
Molec. Cell. Biol.
8:3988-3996; Vincent et al. (1990)
Vaccines
90 (Cold Spring Harbor Laboratory Press); Carter, B. J. (1992)
Current Opinion in Biotechnology
3:533-539; Muzyczka, N. (1992)
Current Topics in Microbiol. and Immunol.
158:97-129; and Kotin, R. M. (1994)
Human Gene Therapy
5:793-801.
Recombinant AAV virion production generally involves cotransfection of a producer cell with an AAV vector plasmid and a helper construct which provides AAV helper functions to complement functions missing from the AAV vector plasmid. In this manner, the producer cell is capable of expressing the AAV proteins necessary for AAV replication and packaging. The AAV vector plasmid will include the DNA of interest flanked by AAV ITRs which provide for AAV replication and packaging functions. AAV helper functions can be provided via an AAV helper plasmid that includes the AAV rep and/or cap coding regions but which lacks the AAV ITRs. Accordingly, the helper plasmid can neither replicate nor package itself. The producer cell is then infected with a helper virus to provide accessory functions, or with a vector which includes the necessary accessory functions. The helper virus transactivates the AAV promoters present on the helper plasmid that direct the transcription and translation of AAV rep and cap regions. Upon subsequent culture of the producer cells, recombinant AAV virions harboring the DNA of interest, are produced.
Recombinant AAV virions have been shown to exhibit tropism for respiratory epithelial cells (Flotte et al. (1992)
Am. J. Respir. Cell Mol. Biol.
7:349-356; Flotte et al. (1993)
J. Biol. Chem.
268:3781-3790; Flotte et al. (1993)
Proc. Natl. Acad. Sci. USA
90:10613-10617) and neurons of the central nervous system (Kaplitt et al. (1994)
Nature Genetics
8:148-154). These cell
Byrne Barry J.
Kessler Paul D.
Kurtzman Gary J.
Podsakoff Gregory M.
Avigen, Inc.
Crouch Deborah
Robins & Pasternak LLP
LandOfFree
Adeno associated virus vectors for the treatment of a... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Adeno associated virus vectors for the treatment of a..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Adeno associated virus vectors for the treatment of a... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3074076